JP7631234B2 - Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞 - Google Patents

Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞 Download PDF

Info

Publication number
JP7631234B2
JP7631234B2 JP2021570724A JP2021570724A JP7631234B2 JP 7631234 B2 JP7631234 B2 JP 7631234B2 JP 2021570724 A JP2021570724 A JP 2021570724A JP 2021570724 A JP2021570724 A JP 2021570724A JP 7631234 B2 JP7631234 B2 JP 7631234B2
Authority
JP
Japan
Prior art keywords
cells
population
car
human
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534962A5 (cg-RX-API-DMAC7.html
JP2022534962A (ja
Inventor
シュエ,トンユアン
エー. ホーン,デヴィッド
エリザベス ブッデ,リファ
フォーマン,スティーブ
リアル,マリッサ エム. デル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2022534962A publication Critical patent/JP2022534962A/ja
Publication of JP2022534962A5 publication Critical patent/JP2022534962A5/ja
Application granted granted Critical
Publication of JP7631234B2 publication Critical patent/JP7631234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021570724A 2019-05-31 2020-06-01 Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞 Active JP7631234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855906P 2019-05-31 2019-05-31
US62/855,906 2019-05-31
PCT/US2020/035579 WO2020243713A2 (en) 2019-05-31 2020-06-01 Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies

Publications (3)

Publication Number Publication Date
JP2022534962A JP2022534962A (ja) 2022-08-04
JP2022534962A5 JP2022534962A5 (cg-RX-API-DMAC7.html) 2023-06-09
JP7631234B2 true JP7631234B2 (ja) 2025-02-18

Family

ID=71842756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570724A Active JP7631234B2 (ja) 2019-05-31 2020-06-01 Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞

Country Status (6)

Country Link
US (1) US12565658B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976794A2 (cg-RX-API-DMAC7.html)
JP (1) JP7631234B2 (cg-RX-API-DMAC7.html)
CN (1) CN114040978B (cg-RX-API-DMAC7.html)
CA (1) CA3142159A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020243713A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384823A (zh) 2014-08-26 2016-03-09 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
CN104877032B (zh) * 2015-06-26 2018-12-11 中国医学科学院血液病医院(血液学研究所) Cd33特异性嵌合抗原受体及其应用
HK1256130A1 (zh) 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
AU2018269194B2 (en) 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
CN107353343A (zh) * 2017-07-04 2017-11-17 武汉波睿达生物科技有限公司 一种靶向表达cd33表面抗原的细胞的嵌合抗原受体
US20210017277A1 (en) 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384823A (zh) 2014-08-26 2016-03-09 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用

Also Published As

Publication number Publication date
WO2020243713A2 (en) 2020-12-03
US20220213489A1 (en) 2022-07-07
US12565658B2 (en) 2026-03-03
JP2022534962A (ja) 2022-08-04
EP3976794A2 (en) 2022-04-06
WO2020243713A3 (en) 2021-01-07
CN114040978B (zh) 2025-10-17
CN114040978A (zh) 2022-02-11
CA3142159A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
AU2023278069B2 (en) Chimeric antigen receptor T cells targeting the tumor microenvironment
Albert et al. From mono-to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
Mamonkin et al. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Vallera et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function
Batlevi et al. Novel immunotherapies in lymphoid malignancies
JP7461620B2 (ja) 治療用化合物及び方法
US20180371052A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
CN112584844A (zh) 用于治疗血液系统恶性肿瘤的基因组编辑的恒定自然杀伤t(inkt)细胞
CA3090546A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
WO2018132506A1 (en) Chimeric antigen receptors based on alternative signal 1 domains
JP7593646B2 (ja) Baff-r/cd19を標的としたキメラ抗原受容体修飾t細胞とその使用
US11352434B2 (en) Chimeric antigen receptors targeting CD37
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors
KR20210081346A (ko) Nk 관여 분자 및 이의 사용 방법
Guo et al. Humanized CD30-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against Hodgkin’s lymphoma cells
Alviano et al. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies
Heiblig et al. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors
US12565658B2 (en) CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies
WO2022092277A1 (ja) Cxcl12受容体発現キメラ抗原受容体(car)-t細胞
RU2812481C2 (ru) Вовлекающие nk молекулы и способы их применения
Kuo Meditope-Enabled Chimeric Antigen Receptor Confers New Functionality to T Cells
JP2025516531A (ja) 高リスクまたは再発性小児急性リンパ芽球性白血病のcd19/22 car t細胞処置
WO2023133488A1 (en) Methods of cell ablation
Turazzi BAFF RECEPTOR (BAFF-R) CAR-REDIRECTED T CELLS: A NOVEL TOOL TO TREAT HIGH RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150